Replimune Group is a biotechnology company focused on developing oncolytic virus therapies for cancer treatment. Its core products include RP1, an investigational therapy designed to selectively target and destroy cancer cells while stimulating an immune response. The company operates primarily in the healthcare sector, with its main revenue sources stemming from research collaborations and potential future product sales.
The investment profile of Replimune Group is more aligned with growth investors, given its focus on innovative therapies and potential for future revenue generation. The company is in the early stages of commercialization, which may appeal to those seeking high-risk, high-reward opportunities.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-09-12 | Hold | Sell | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-09-04 | Buy | Hold | Weak fundamentals and high volatility raise concerns. |
| 2026-08-27 | Hold | Buy | Strong momentum, but fundamentals show significant losses. |
| 2026-08-20 | Buy | Hold | High volatility and negative EPS raise concerns. |
| 2026-08-11 | Hold | Buy | Strong momentum, but fundamentals show significant losses. |
| 2026-08-01 | — | Hold | High volatility; uncertain fundamentals warrant caution. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-08-07 | BMO Capital | Target Raised | 16 → 20 | 12.86 |
| 2026-08-07 | Wedbush | Update | — → 19 | 12.86 |
| 2026-08-04 | Leerink Partners | Update | — → 17 | 11.91 |
| 2026-07-31 | Wedbush | Update | — → 12 | 5.41 |
| 2026-06-30 | Wedbush | Target Raised | 6 → 9 | 11.2 |
| 2026-06-30 | BMO Capital | Rating Upgraded | — → 16 | 11.2 |
| 2026-02-05 | Piper Sandler | Target Raised | 13 → 14 | 7 |
| 2025-11-03 | BMO Capital | Rating Upgraded | — → 11 | 9.73 |
| 2025-10-27 | H.C. Wainwright | Rating Upgraded | — → 12 | 8.8 |
| 2025-10-20 | Wedbush | Update | — → 18 | 9.15 |
